These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22343624)

  • 41. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening.
    Goede SL; van Roon AH; Reijerink JC; van Vuuren AJ; Lansdorp-Vogelaar I; Habbema JD; Kuipers EJ; van Leerdam ME; van Ballegooijen M
    Gut; 2013 May; 62(5):727-34. PubMed ID: 22490518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
    Bretagne JF; Carlo A; Piette C; Rousseau C; Cosson M; Lièvre A
    Br J Cancer; 2021 Nov; 125(11):1494-1502. PubMed ID: 34511603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The economic evaluation of screening for colorectal cancer: Case of Iran.
    Barouni M; Ghaderi H; Shahmoradi MK
    Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study.
    Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I
    BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
    JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers.
    Shuhaibar M; Walsh C; Lindsay F; Lee N; Walsh P; O'Gorman P; Boran G; McLoughlin R; Qasim A; Breslin N; Ryan B; O'Connor H; O'Morain C
    Ir J Med Sci; 2011 Mar; 180(1):103-8. PubMed ID: 20953981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of single colonoscopy versus single fecal test for colorectal cancer diagnosis and treatment.
    Ishibashi F; Suzuki S; Kobayashi K; Tanaka R; Kawakami T; Mochida K; Nagai M; Ishibashi Y; Morishita T
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1328-1335. PubMed ID: 38348570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
    Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
    J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FIT for the future: a case for risk-based colorectal cancer screening using the faecal immunochemical test.
    Cooper JA; Moss SM; Smith S; Seaman HE; Taylor-Phillips S; Parsons N; Halloran SP
    Colorectal Dis; 2016 Jul; 18(7):650-3. PubMed ID: 27135192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.
    Parekh M; Fendrick AM; Ladabaum U
    Aliment Pharmacol Ther; 2008 Apr; 27(8):697-712. PubMed ID: 18248653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis.
    van Hees F; Habbema JD; Meester RG; Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG
    Ann Intern Med; 2014 Jun; 160(11):750-9. PubMed ID: 24887616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
    Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests.
    Meester RGS; Ladabaum U
    JNCI Cancer Spectr; 2024 Sep; 8(5):. PubMed ID: 39240660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
    Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
    Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.